- All sections
- C - Chemistrymetallurgy
- C07D - Heterocyclic compounds
- C07D 307/84 - Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
Patent holdings for IPC class C07D 307/84
Total number of patents in this class: 122
10-year publication summary
|
10
|
16
|
6
|
7
|
5
|
6
|
3
|
5
|
4
|
1
|
| 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
Principal owners for this class
| Owner |
All patents
|
This class
|
|---|---|---|
| Bristol-myers Squibb Company | 4774 |
26 |
| Katholieke Universiteit Leuven | 1261 |
7 |
| Janssen Pharmaceutica N.V. | 3209 |
4 |
| Merck Sharp & Dohme Corp. | 2183 |
3 |
| Cocrystal Pharma, Inc. | 44 |
3 |
| Shanghai Institute of Materia Medica, Chinese Academy of Sciences | 862 |
3 |
| The United States of America, as represented by the Secretary, Department of Health and Human Services | 2980 |
3 |
| Firmenich Incorporated | 158 |
3 |
| Sanofi | 4278 |
3 |
| Allergan, Inc. | 2195 |
2 |
| Abbvie Inc. | 1840 |
2 |
| Northwestern University | 3528 |
2 |
| Bionomics Limited | 85 |
2 |
| Ideaya Biosciences, Inc. | 153 |
2 |
| Lek Pharmaceuticals d.d. | 188 |
2 |
| Memorial Sloan-Kettering Cancer Center | 2018 |
2 |
| The Scripps Research Institute | 1342 |
2 |
| Sunshine Lake Pharma Co., Ltd. | 620 |
2 |
| Calico Life Sciences LLC | 106 |
2 |
| Biohaven Therapeutics Ltd. | 154 |
2 |
| Other owners | 45 |